Table 4 Incidence of venous thromboembolism among medical inpatients receiving enoxaparin versus UFH prophylaxis by dosage and duration of prophylaxis received
From: Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients
Outcome (N [%]) | |||||
|---|---|---|---|---|---|
Prophylaxis Received/Dosage or Days | N | % of Patients | DVT | PE | VTE (DVT and/or PE) |
Dosage: | |||||
Enoxaparin | |||||
30–40 mg | 186 | 38.8% | 0 (0.0) | 0 (0.0) | 0 (0.0) |
50–60 mg | 293 | 61.2% | 8 (2.7) | 0 (0.0) | 8 (2.7) |
UFH | |||||
5,000-<10,000 IU | 414 | 14.5% | 47 (11.4) | 8 (1.93) | 52 (12.6) |
10,000 IU | 2,221 | 78.0% | 109 (4.9) | 23 (1.04) | 121 (5.4) |
>10,000–15,000 IU | 214 | 7.5% | 7 (3.3) | 1 (0.5) | 7 (3.3) |
Prophylaxis days: | |||||
Enoxaparin | |||||
1–2 days | 74 | 15.4% | 4 (5.4) | 0 (0.0) | 4 (5.4) |
3–4 days | 36 | 7.5% | 2 (5.6) | 0 (0.0) | 2 (5.6) |
5–6 days | 123 | 25.7% | 2 (1.6) | 0 (0.0) | 2 (1.6) |
> 6 days | 246 | 51.4% | 0 (0.0) | 0 (0.0) | 0 (0.0) |
UFH | |||||
1–2 days | 831 | 29.3% | 109 (13.1) | 22 (2.7) | 120 (14.4) |
3–4 days | 227 | 8.0% | 21 (9.25) | 2 (0.9) | 23 (10.1) |
5–6 days | 608 | 21.4% | 15 (2.5) | 4 (0.7) | 15 (2.5) |
> 6 days | 1,171 | 41.3% | 18 (1.5) | 4 (0.3) | 22 (1.9) |